ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy
ImmunityBio announced five U.S. patents protecting its Anktiva-plus-BCG bladder cancer therapy through 2035, and an exclusive supply deal for the Tokyo-172 BCG strain.
Technology
